我们是否需要一套不同的肿瘤免疫治疗反应评估标准？
Do we need a different set of response assessment criteria for tumor immunotherapy?
机构信息
Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California 90095-1782, USA.
出版信息
Clin Cancer Res. 2009 Dec 1;15(23):7116-8. doi: 10.1158/1078-0432.CCR-09-2376. Epub 2009 Nov 24.
Abstract
Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.
摘要
肿瘤免疫疗法引起的肿瘤退缩可能先于炎症变化。这给肿瘤免疫疗法的反应率评估带来了混淆。在本期《临床癌症研究》中，Wolchok 等人试图通过提出一组称为免疫相关反应标准的新标准来解决这一特殊性。
Zotero 插件